Metastatic Breast Cancer
Conditions
Keywords
metastatic breast cancer, triple negative breast cancer, gemcitabine, RAD001
Brief summary
This study consists of two parts. In a phase Ib part, investigators will explore the recommended dose of gemcitabine, cisplatin, and RAD001 combination in patients with metastatic TNBC. After completing the phase Ib part, investigators will review the data and discuss with Novartis before the start of a phase II part. In the phase II part, investigators will compare the efficacy of the gemcitabine and cisplatin with or without RAD001 in patients with metastatic TNBC.
Detailed description
PIK3CA active mutations are the most frequent genetic event in breast cancer, including in TNBC which presents activated PI3K/AKT signaling due to PIK3CA mutation or PTEN deficiency. TNBC cell lines having activated PI3K/AKT signaling showed a high sensitivity to PI3K/mTOR inhibitors. RAD001 is a potent mTOR complex 1 inhibitor and showed to enhance cisplatin or gemcitabine induced apoptosis by inhibiting p53 induced p21 expression. This study consists of two parts. In a phase Ib part, investigators will explore the recommended dose of gemcitabine, cisplatin, and RAD001 combination in patients with metastatic TNBC. After completing the phase Ib part, investigators will review the data and discuss with Novartis before the start of a phase II part. In the phase II part, investigators will compare the efficacy of the gemcitabine and cisplatin with or without RAD001 in patients with metastatic TNBC.
Interventions
DRUGRAD001
Afinitor 5mg qd. po.
DRUGGemcitabine
gemcitabine 800mg/m2 iv. D1 and D8 every 3 weeks
DRUGCisplatin
cisplatin 30mg/m2 iv. D1 and D8 every 3 weeks
Sponsors
National Cancer Center, Korea
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Females with histologically confirmed, metastatic or stage IV breast cancer * ER/PgR negative or poor (Allred score ≤ 3/8) and HER2 negative breast cancer * ECOG performance status 0-2 * Age ≥ 20 years * Previously treated by anthracycline and taxane in adjuvant/neoadjuvant or metastatic setting * ≤ 2 chemotherapy regimens for metastatic disease * Radiological or objective evidence of recurrence or progression on or after the last systemic therapy prior to enrolment. * CNS metastasis is permitted if asymptomatic and not requiring treatment with steroids and is documented to be non-progressing at study entry * Presence of measurable or evaluable disease by RECIST 1.1 criteria * Adequate hematopoietic function: Absolute granulocyte count ≥1,500/mm3, platelet ≥100,000/mm3, hemoglobin ≥ 10g/mm3 * Adequate hepatic function: total bilirubin ≤ 1.5 x upper normal limit (UNL), AST/ALT ≤2.5 x UNL or ≤5 x UNL if presented with hepatic metastasis * Fasting serum cholesterol ≤ 300mg/dl and fasting triglycerides ≤ 2.5 x UNL * Adequate renal function: Serum creatinine ≤1.5mg/dL * Patients should sign a written informed consent before study entry * Patients with positive HBV-DNA of HBsAg at screening must initiate prophylaxis with appropriate antiviral medication at least one week prior to treatment start
Exclusion criteria
* Known active CNS metastasis * Patients who received prior therapy with gemcitabine * Patients with only non-measurable lesions other than bone metastasis (e.g. pleural effusion, ascites). * Patients with more than 3 prior chemotherapy lines for treating metastatic breast cancer. * Patients who received prior therapy with mTOR inhibitor or PI3K inhibitor * Known hypersensitivity to mTOR inhibitors, e.g. Sirolimus (rapamycin). * Radiotherapy within four weeks prior to enrolment, except radiotherapy to the bone for analgesic purpose or for lytic lesions at risk of fracture. Patients must have recovered from radiotherapy toxicities prior to enrolment. * Patients who have history of cancer other than in situ uterine cervix cancer or nonmelanotic skin cancer * Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus * Active ulceration of upper gastrointestinal tract * Other concurrent severe and/or uncontrolled conditions (e.g. uncontrolled diabetes mellitus, active untreated or uncontrolled infection, chronic obstructive or chronic restrictive pulmonary disease including dyspnea at rest from any cause) that could cause unacceptable safety risks or compromise compliance with the protocol. * Patients with a known history of HIV seropositivity. Screening for HIV infection at baseline is not required. * Significant symptomatic deterioration of lung function. If clinically indicated, pulmonary function tests including measures of predicted lung volumes, DLco, O2 saturation at rest on room air should be considered to exclude restrictive pulmonary disease, pneumonitis or pulmonary infiltrates. * Patients being treated with drugs recognized as being strong inhibitors or inducers of the isoenzyme CYP3A at enrolment (rifabutin, rifampicin, clarithromycin, ketoconazole, itraconazole, voriconazole, ritonavir, telithromycin) continuously for at least 7 days during any time period in the last 2 weeks prior to enrolment * Known hypersensitivity to protocol treatment * Pregnant or breast feeding * Peripheral neuropathy ≥ grade 2 (NCI CTCAE version 4.0) at randomization * Patients unwilling to or unable to comply with the protocol
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The recommended dose of the combination of gemcitabine, cisplatin and RAD001 (everolimus) in patients with metastatic triple-negative breast cancer | up to 1 year | phase IB part |
| Efficacy of gemcitabine and cisplatin with or without RAD001 in patients with metastatic triple-negative breast cancer by evaluating progression free survival (PFS) | up to 5 years | phase II part |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival (OS) | up to 5 years | phase Ib and phase II |
| number of patients with adverse events as a measure of safety and tolerability | up to 5 years | phase Ib and phase II |
| check biomarkers associated with the response of RAD001: angiogenesis, metabolism, immune cells profiles | up to 5 years | phaseIb and phaseII |
| The maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of gemcitabine/cisplatin/RAD001 | up to 1 year | phase Ib part |
| objective response rate | up to 1 year | phase Ib and phase II |
Countries
South Korea
Outcome results
None listed